Navigation Links
Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10
Date:10/11/2011

act is significantly reduced and, as the iron is retained within the product if it is not absorbed, it is expected this will significantly reduce the risk of unwanted side effects within the gastrointestinal tract.

The international, multicentre, randomised, double-blind and placebo controlled AEGIS 1 and AEGIS 2 studies will investigate the potential of ST10 as a twice-daily treatment of IDA in subjects with Ulcerative Colitis (UC) or Crohn's disease respectively where oral ferrous preparations have failed or cannot be used.  The studies are each enrolling 120 patients and will measure patients' change in haemoglobin concentration from baseline to week 12.  Initial results from both studies are expected to be reported in late 2012 and, if positive, will be promptly followed by filings of marketing authorisation applications in key pharmaceutical markets.  In addition, Shield is planning to initiate a Phase 3 study of ST10 for the treatment of IDA in patients with chronic kidney disease in 2012.  

Data provided by IMS suggests that the iron market was worth $2.4 billion in 2010, of which 55% of revenues were generated from oral iron therapies.

There are currently no curative treatments available for UC or Crohn's and so treatment options are restricted to controlling symptoms, maintaining remission and preventing relapse.  IDA in both is a chronically debilitating disorder which has a significant impact on patients' quality of life and, as a result, its treatment is an important aspect of disease management.  Characteristic symptoms of IDA include chronic fatigue, headache and subtle impairment of cognitive function.  Up to one third of subjects with UC and Crohn's suffer from recurrent anaemia, with hospitalisation required in severe cases.

About Shield Therapeutics

Shield Therapeutics (http://www.shieldtherapeutics.com), founded in 2008, is an ind
'/>"/>

SOURCE Shield Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cord Blood America Enters Agreement With Regence, Serving BlueCross and BlueShield Programs in the Northwest U.S. and Mountain Regions
2. TCT 2009 to Feature vProtect(TM) Luminal Shield, a Novel Treatment Designed for Soft Coronary Lesions from Prescient Medical
3. vProtect(TM) Luminal Shield Stabilizes Life-Threatening Plaque
4. SyntheMed Announces FDA Clearance of SinusShield(TM)
5. NanoVibronix Receives FDA Clearance for its PainShield(TM) MD Device
6. United Therapeutics Announces Proposed Private Offering of $210 Million of Convertible Senior Notes and Authorization of Stock Repurchase Program
7. United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to $45 Million to Support Glycobiology Antiviral Program
8. Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology
9. Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
10. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
11. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)...  Neurotech Pharmaceuticals, Inc., announced today the first ... 2 clinical trial of NT-503 Encapsulated Cell Therapy ... choroidal neovascularization secondary to age related macular degeneration ... growth factor (VEGF) receptor protein continuously produced by ... proof-of-concept study will evaluate NT-503 ECT as a ...
(Date:9/2/2015)... NESS ZIONA, Israel , September ... BVXV, TASE: BVXV) today announced the intent of the National ... U.S. National Institutes of Health (NIH) within the Department of ... 2 trial to be held in the United ... examine the use of BiondVax,s universal flu vaccine candidate, Multimeric-001 ...
(Date:9/2/2015)... San Diego, CA (PRWEB) , ... September 02, ... ... from troubleshooting faults in manufacturing equipment, to creating professional commercial video content, to ... beautifully detailed views of fascinating events that go by too quickly to process ...
(Date:9/1/2015)... , Sept. 1, 2015  ContraVir Pharmaceuticals, Inc. (NASDAQ: ... development and commercialization of targeted antiviral therapies, announced today ... 17 th Annual Global Investment Conference sponsored by ... 8-10, 2015 at The St. Regis Hotel in ... James Sapirstein , Chief Executive Officer, will provide ...
Breaking Biology Technology:Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3ContraVir to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2
... VPHM ) reported today its financial results for ... In 2010, we: Achieved a record $439 ... net sales of Cinryze® (C1 esterase inhibitor [human]); Attained ... growth over the prior year; GAAP net income reached $126 ...
... in German . , They have been used ... now they are making rapid inroads in high performance applications: ... phones and digital cameras. The automotive industry, for instance, has ... using them in driver assistance systems from parking aids ...
... Feb. 23, 2011 Scarguard Labs, LLC, a closely ... and other dermatological problems through the use of multi-technology ... today that they have received approval from Health Canada ... "We are very pleased to gain approval ...
Cached Biology Technology:ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 2ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 3ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 4ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 5ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 6ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 7ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 8ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 9ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 10ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 11UV-transparent coating for image sensors 2
(Date:8/5/2015)... 5, 2015 The biosensors market is proving ... penetration into newer sectors, and development of devices resulting ... space has seen the entry of multiple participants each ... (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... of the Global Biosensors Market ( http://www.frost.com/nee9 ), ...
(Date:8/3/2015)... , Aug. 3, 2015 Synaptics, Inc. (Nasdaq: ... solutions, today announced that members of the executive management ... Pacific Crest Global Technology Leadership Forum on Tuesday, August ... will be held at the Sonnenalp Resort in ... presentation may include forward-looking information. An audio webcast of ...
(Date:7/31/2015)... , 31 de julho de 2015 A ... www.icg-10.org ) será realizada pela BGI de 22-25 de outubro ... A conferência está celebrando seu 10 o. ... a ICG se tornou uma das reuniões mais influentes ... encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... WASHINGTON, Oct. 9 -- Medical research is a cornerstone ... Meeting of the Optical Society (OSA), being held Oct. ... FiO 2008 will take place alongside Laser Science ... Division of Laser Science. Reporters interested in obtaining ...
... between the promise of victory and the dread of defeat ... in the brain,s architecture, according to a new imaging study. ... identified distinct brain regions with competing responses to risk. ... behind the forehead involved in analysis and planning. ...
... North Carolina State University researchers are launching a new ... throughout the state, decrease the cost of providing the ... hopefully contribute to the establishment of nationwide standards for ... led by Dr. Ann H. Ross, has received a ...
Cached Biology News:Where optics meets medicine 2Where optics meets medicine 3Where optics meets medicine 4Where optics meets medicine 5Where optics meets medicine 6Where optics meets medicine 7Risk and reward compete in brain 2NC State takes lead in crime scene investigation training 2
Vitronectin Immunogen: Purified, full length, native human protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... Guava has made microcapillary flow cytometry accessible ... experts alike will appreciate the latest addition ... Pluseasy to use, surprising affordable, and very ... system includes such features as absolute cell ...
...
Fingerprinting II Basic software is used for analyzing fingerprint sample types (electrophoretic gels, HPLC and other chromatographic patterns, spectrophotometric and densitometric curves)....
Biology Products: